key: cord-1019853-nq30dgtn authors: Rowley, Anne H. title: Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease: Two Different Illnesses with Overlapping Clinical Features date: 2020-06-22 journal: J Pediatr DOI: 10.1016/j.jpeds.2020.06.057 sha: d5b21168e6132a14ea7f7c76dbe56a7150013df1 doc_id: 1019853 cord_uid: nq30dgtn nan In late April 2020, alarming news emerged from Europe that a group of children with evidence of recent SARS-CoV-2 infection had developed a severe illness, manifesting fever, hypotension requiring inotropic support, severe abdominal pain, and myocardial dysfunction with marked elevation in cardiac damage markers. This syndrome has been named Pediatric Multisystem Inflammatory Syndrome in Europe, and Multisystem Inflammatory Syndrome in Children (MIS-C) by the U.S. Centers for Disease Control (CDC). As case series began to be reported, the similarities in the clinical features among the cases were striking, as were the frequent additional laboratory features of lymphopenia, thrombocytopenia, and cytokine storm with marked elevation in serum inflammatory markers including interleukin-6 (IL-6 )(1-6,6A,6B). Most of these children recovered, although infrequently patients have required extracorporeal membrane oxygenation, with a fatal outcome from complications of this therapy reported rarely (3,6A) . Patients were managed in different ways, often with corticosteroid therapy, intravenous gammaglobulin, and, less often, anti-cytokine therapies, and the vast majority appeared to require intensive care therapy only for a matter of days, regardless of the management strategy (1, 5, 6, 6A,6B) . Some patients had one or more clinical features that can be observed in many illnesses of childhood including Kawasaki disease, such as conjunctival injection, oral erythema, and rash. Classic KD diagnostic criteria were rarely present. Moreover, the median age of the cases was 9-10 years in the largest series reported to date (1, 7) , which is in marked contrast to KD, which occurs predominately in children <5 years of age and with a peak incidence at ~10 months of age (8, 9) . Asian children have the highest attack rates of KD, whereas the highest rates of MIS-C have been in children of African descent (3, 10) . These marked epidemiologic differences make it clear that the two conditions are not the same. Because of a concern that MIS-C might potentially encompass a wider range of clinical features than those observed in the reported cases, the CDC developed a broad case definition. Unfortunately, the case definition as it currently stands is problematic, because patients with many infectious and inflammatory conditions of childhood that are not MIS-C fulfill the case definition. This includes patients with acute COVID-19 infection (eg, acute infection with fever, rash, diarrhea, and a minimally elevated C-reactive protein level), classic KD (e.g., a child with KD who has rash as one of the diagnostic features and mild hepatitis or diarrhea), other viral infections (e.g. one of many that could cause fever, rash, cough, and an increase in neutrophils in peripheral blood), systemic onset juvenile idiopathic arthritis (e.g., fever, rash, an increase in neutrophils in peripheral blood, elevated acute phase reactants), and so on. Moreover, on my recent clinical service, I noted an increase in patient transfers from referring hospitals of children with low grade fever for one day, rash, and mild abdominal discomfort, for evaluation for possible MIS-C. These children arrived appearing well, with completely normal blood pressure and heart rate and minimally elevated acute phase reactants. Presumably, all the media publicity about MIS-C is raising concern among practitioners about missing this diagnosis, potentially resulting in an increase in hospital admissions for routine minor childhood illnesses, and a likely inflated number of reported cases. Moreover, a rapid or presumptive diagnosis of MIS-C, which remains uncommon, also has the potential to result in premature diagnostic Many favor the theory that diverse infectious agents (including coronavirus) can trigger a "final common pathway" of immune dysregulation causing KD in a genetically susceptible individual. However, the idea that a genetically predisposed individual who is immunologically susceptible to multiple infections could be triggered only once (since KD rarely recurs) does not fit with our present understanding of human immunology. This hypothesis would also predict that KD could occur at any age, whereas the age distribution of KD is quite classic for a disease caused by a single ubiquitous infectious agent. One also cannot explain the occurrence of welldocumented epidemics and outbreaks of KD with geographic wave-like spread of illness (15) based on a theory of diverse infectious triggers. individual country, and also appear to decrease following a decline in COVID-19 cases (16) . It is hoped that when the SARS-CoV-2 pandemic is finally overcome, potentially by vaccination, MIS-C will no longer be a clinical issue. Although the etiologic agent of KD presently remains unclear, research studies support a ubiquitous RNA virus, different from presently known human viruses, that forms intracytoplasmic inclusion bodies in tissues from patients with KD (17, 18) . We have identified a protein epitope of the putative agent recognized by the antibody response in KD patients, with substantial progress in developing the first-ever serologic assay for KD (18) . Development of a diagnostic test for KD would enable distinguishing KD from the many infectious and inflammatory conditions in the differential diagnosis (19) , which presently should include MIS-C. In the meantime, research is urgently needed to identify the pathogenesis of MIS-C, which is currently unknown but bears similarities to the cytokine storm observed in adult patients with COVID-19 during their second week of illness (20) . No virus can be isolated from cultures of clinical specimens (21, 22) Virus can be isolated from cultures of clinical specimens No coronavirus is identified by high throughput RNA sequencing of tissues from KD patients (18, 23, 24) Virus can be identified by high throughput RNA sequencing of tissues from infected patients No signal exists for serologic cross reactivity with coronaviruses, even using new highly sensitive VirScan method (21) (22) (23) Serologic cross reactivity occurs with other coronaviruses, particularly those in the same subfamily (25) Recurrence is rare; disease is rare in adolescents and adults Immunity wanes and infections with most coronaviruses generally recur lifelong (26) Numerous RT-PCR studies investigating coronavirus as potential cause have been negative Viral RNA is consistently detected in patient samples by RT-PCR Inclusion bodies have been identified in ciliated bronchial epithelium that are targeted by antibodies from KD patients (18) ; virus-like particles found adjacent to inclusion bodies are about 50 nm in diameter (17) No inclusion bodies are identifiable in bronchial epithelium; virus particles are ~120 nm in diameter Patients have an antigen-driven immune response that is not directed at coronavirus (18) Immune response is directed at coronavirus Coronary artery aneurysms occur; thrombosis is limited to within aneurysms Hypercoagulability with vascular thrombosis at multiple sites is characteristic of SARS-CoV-2 infection; coronary artery aneurysms are not reported in acute SARS-CoV-2 infection; autopsy in the only pediatric patient reported to date with cardiac death from SARS-CoV-2 showed eosinophilic myocarditis with no evidence of vascular inflammation (27) Epidemiologic and histologic evidence supports the hypothesis of persistent infection (28, 29) There is no persistent infection Median age of patients with KD-associated shock is 2.8 yrs (30) Median age of patients with SARS-CoV-2 associated pediatric shock is is 9-10 years (1, 7) Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series Hyperinflammatory shock in children during COVID-19 pandemic An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Severe SARS-CoV-2 Infection in Children With Suspected Acute Abdomen: A Case Series From a Tertiary Hospital in Spain Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Disease of Childhood (MIS-C) Associated with SARS-CoV-2 Infection Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 Hospitalizations for Kawasaki syndrome among children in the United States Descriptive epidemiology of Kawasaki disease in Japan Kawasakilike multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study Intestinal involvement in Kawasaki disease Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis Sohn s. NT-pro BNP: A new diagnostic screening tool for Kawasaki disease COVID-19 and Kawasaki Disease in Children The Epidemiology and Pathogenesis of Kawasaki Disease SARS-CoV-2-related pediatric inflammatory multisystem syndrome, an epidemiologic study Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease A Protein Epitope Targeted by the Antibody Response to Kawasaki Disease Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association Clinical features of patients infected with 2019 novel coronavirus in Wuhan Kawasaki syndrome: description of two outbreaks in the United States An epidemic of Kawasaki syndrome in Hawaii High-Throughput Screening of Kawasaki Disease Sera for Antiviral Antibodies Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63 The time course of the immune response to experimental coronavirus infection of man Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c) Predicting the characteristics of the aetiological agent for Kawasaki disease from other paediatric infectious diseases in Japan RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease Recognition of a Kawasaki disease shock syndrome